ArticleJournal of managed care & specialty pharmacy2021
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Measuring and valuing spillover effects in caregivers and families: A scoping review.PloS one · 2026Article
- Stakeholder survey about broad elements of value in health technology assessment in Australia: industry and academia more similar than different.International journal of technology assessment in health care · 2025Article
- Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective.Applied health economics and health policy · 2024Article
- Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements.Frontiers in pharmacology · 2023Review
- Health care utilization and expenditures of parents of children with and without hemophilia A.Journal of managed care & specialty pharmacy · 2022Article
- Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases.American journal of ophthalmology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.